{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Neuroendocrine+Carcinomas&page=5",
    "query": {
      "condition": "Neuroendocrine Carcinomas",
      "page": 5
    },
    "page_size": 10
  },
  "pagination": {
    "page": 5,
    "page_size": 10,
    "total_count": 950,
    "total_pages": 95,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Neuroendocrine+Carcinomas&page=6&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Neuroendocrine+Carcinomas&page=4&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-11-17T06:35:50.917Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT00942682",
      "title": "Sorafenib in Combination With RAD001 in Patients With Advanced Neuroendocrine Tumors",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Neuroendocrine Tumor",
        "Carcinoid Tumor",
        "Pancreatic Neuroendocrine Tumor"
      ],
      "interventions": [
        {
          "name": "Sorafenib",
          "type": "DRUG"
        },
        {
          "name": "RAD001",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Dana-Farber Cancer Institute",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 21,
      "start_date": "2009-07",
      "completion_date": "2013-03",
      "has_results": false,
      "last_update_posted_date": "2014-04-29",
      "last_synced_at": "2026-11-17T06:35:50.917Z",
      "location_count": 1,
      "location_summary": "Boston, Massachusetts",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00942682"
    },
    {
      "nct_id": "NCT06176989",
      "title": "Enasidenib in IDH2-Mutated Malignant Sinonasal and Skull Base Tumors",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Metastatic Chondrosarcoma",
        "Locally Advanced Chondrosarcoma",
        "Metastatic Sinonasal Adenocarcinoma",
        "Locally Advanced Sinonasal Adenocarcinoma",
        "Metastatic Large-cell Neuroendocrine Carcinoma",
        "Locally Advanced Large-cell Neuroendocrine Carcinoma",
        "Metastatic Olfactory Neuroblastoma",
        "Locally Advanced Olfactory Neuroblastoma",
        "Metastatic Sinonasal Undifferentiated Carcinoma",
        "Locally Advanced Sinonasal Undifferentiated Carcinoma"
      ],
      "interventions": [
        {
          "name": "Enasidenib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "120 Years",
        "sex": "ALL",
        "summary": "18 Years to 120 Years"
      },
      "enrollment_count": 40,
      "start_date": "2024-03-04",
      "completion_date": "2030-12-31",
      "has_results": false,
      "last_update_posted_date": "2026-11-05",
      "last_synced_at": "2026-11-17T06:35:50.917Z",
      "location_count": 1,
      "location_summary": "Bethesda, Maryland",
      "locations": [
        {
          "city": "Bethesda",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06176989"
    },
    {
      "nct_id": "NCT03780517",
      "title": "Safety, Efficacy, and Tolerability of BOS172738 in Patients With Advanced Rearranged During Transfection (RET) Gene-Altered Tumors",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Advanced Nonhaematologic Malignancies"
      ],
      "interventions": [
        {
          "name": "BOS172738",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Boston Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 117,
      "start_date": "2018-12-12",
      "completion_date": "2023-09-26",
      "has_results": false,
      "last_update_posted_date": "2023-10-30",
      "last_synced_at": "2026-11-17T06:35:50.917Z",
      "location_count": 2,
      "location_summary": "Philadelphia, Pennsylvania • Houston, Texas",
      "locations": [
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        },
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03780517"
    },
    {
      "nct_id": "NCT04157985",
      "title": "Evaluating Length of Treatment With PD-1/PD-L1 Inhibitor in Advanced Solid Tumors",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Advanced Solid Tumors",
        "NSCLC",
        "Bladder Cancer",
        "HNSCC",
        "Renal Cancer",
        "Melanoma",
        "Anal Cancer",
        "Colorectal Cancer",
        "Cholangiocarcinoma",
        "Gastric Cancer",
        "Hepatocellular Carcinoma",
        "Merkel Cell Carcinoma",
        "Cervical Cancer"
      ],
      "interventions": [
        {
          "name": "Continue PD-1/PD-L1 Inhibitors treatment",
          "type": "DRUG"
        },
        {
          "name": "Discontinue PD-1/PD-L1-1 inhibitor",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Dan Zandberg",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 161,
      "start_date": "2019-11-15",
      "completion_date": "2025-11-07",
      "has_results": false,
      "last_update_posted_date": "2025-12-11",
      "last_synced_at": "2026-11-17T06:35:50.917Z",
      "location_count": 1,
      "location_summary": "Pittsburgh, Pennsylvania",
      "locations": [
        {
          "city": "Pittsburgh",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04157985"
    },
    {
      "nct_id": "NCT04709276",
      "title": "A Study of Chemoimmunotherapy for the Treatment of Men With Neuroendocrine or Aggressive Variant Metastatic Prostate Cancer",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Metastatic Prostate Neuroendocrine Carcinoma",
        "Metastatic Prostate Cancer"
      ],
      "interventions": [
        {
          "name": "Nivolumab",
          "type": "DRUG"
        },
        {
          "name": "Ipilimumab",
          "type": "DRUG"
        },
        {
          "name": "Carboplatin",
          "type": "DRUG"
        },
        {
          "name": "Cabazitaxel",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Andrew J. Armstrong, MD",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "MALE",
        "summary": "18 Years and older · Male only"
      },
      "enrollment_count": 41,
      "start_date": "2021-06-07",
      "completion_date": "2028-08",
      "has_results": false,
      "last_update_posted_date": "2026-04-06",
      "last_synced_at": "2026-11-17T06:35:50.917Z",
      "location_count": 3,
      "location_summary": "New York, New York • Durham, North Carolina • Houston, Texas",
      "locations": [
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "Durham",
          "state": "North Carolina"
        },
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04709276"
    },
    {
      "nct_id": "NCT05902520",
      "title": "Adoptive Cell Therapy Using Cancer Specific CD8+ Tumor Infiltrating Lymphocytes in Adult Patients With Solid Tumors",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "HNSCC",
        "Melanoma",
        "Gynecologic Cancer",
        "Colorectal Cancer",
        "Lung Cancer",
        "Urogenital Cancer"
      ],
      "interventions": [
        {
          "name": "DP CD8 TIL",
          "type": "BIOLOGICAL"
        },
        {
          "name": "DP CD8 TIL KD",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Low dose IL-2",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "AgonOx, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 18,
      "start_date": "2023-06-19",
      "completion_date": "2026-12-31",
      "has_results": false,
      "last_update_posted_date": "2026-01-08",
      "last_synced_at": "2026-11-17T06:35:50.917Z",
      "location_count": 1,
      "location_summary": "Portland, Oregon",
      "locations": [
        {
          "city": "Portland",
          "state": "Oregon"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05902520"
    },
    {
      "nct_id": "NCT07328490",
      "title": "Bispecific T-Cell Engager Tarlatamab and TROP2 Targeted Antibody Drug Conjugate Sacituzumab Govitecan in Previously Treated Extensive-Stage Small Cell Lung Cancer and Extrapulmonary Neuroendocrine Cancer",
      "overall_status": "WITHDRAWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Extensive-Stage Small Cell Lung Cancer",
        "Extrapulmonary Neuroendocrine Carcinoma",
        "Small Cell Carcinoma"
      ],
      "interventions": [
        {
          "name": "Tarlatamab",
          "type": "DRUG"
        },
        {
          "name": "Sacituzumab Govitecan",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "120 Years",
        "sex": "ALL",
        "summary": "18 Years to 120 Years"
      },
      "enrollment_count": 0,
      "start_date": "2026-04-25",
      "completion_date": "2026-04-25",
      "has_results": false,
      "last_update_posted_date": "2026-04-28",
      "last_synced_at": "2026-11-17T06:35:50.917Z",
      "location_count": 1,
      "location_summary": "Bethesda, Maryland",
      "locations": [
        {
          "city": "Bethesda",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07328490"
    },
    {
      "nct_id": "NCT03685591",
      "title": "PF-06952229 Treatment in Adult Patients With Advanced Solid Tumors",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Breast Neoplasms",
        "Prostate Neoplasms",
        "Neoplasms, Squamous Cell",
        "Melanoma",
        "Mesothelioma",
        "Pancreatic Neoplasms",
        "Colorectal Neoplasms",
        "Carcinoma, Renal Cell",
        "Liver Neoplasms"
      ],
      "interventions": [
        {
          "name": "PF-06952229",
          "type": "DRUG"
        },
        {
          "name": "Enzalutamide",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Pfizer",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 49,
      "start_date": "2018-10-04",
      "completion_date": "2022-03-30",
      "has_results": true,
      "last_update_posted_date": "2024-06-26",
      "last_synced_at": "2026-11-17T06:35:50.917Z",
      "location_count": 15,
      "location_summary": "Scottsdale, Arizona • Santa Monica, California • Boston, Massachusetts + 6 more",
      "locations": [
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "Santa Monica",
          "state": "California"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03685591"
    },
    {
      "nct_id": "NCT03190213",
      "title": "Pembrolizumab for the Treatment of Recurrent High Grade Neuroendocrine Carcinoma",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Neuroendocrine Tumors"
      ],
      "interventions": [
        {
          "name": "Pembrolizumab Injection",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of Utah",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 6,
      "start_date": "2017-12-04",
      "completion_date": "2019-03-11",
      "has_results": true,
      "last_update_posted_date": "2021-06-22",
      "last_synced_at": "2026-11-17T06:35:50.917Z",
      "location_count": 1,
      "location_summary": "Salt Lake City, Utah",
      "locations": [
        {
          "city": "Salt Lake City",
          "state": "Utah"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03190213"
    },
    {
      "nct_id": "NCT02514824",
      "title": "MLN0128 in Recurrent/Metastatic Merkel Cell Carcinoma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Merkel Cell Carcinoma"
      ],
      "interventions": [
        {
          "name": "MLN0128",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Dana-Farber Cancer Institute",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 9,
      "start_date": "2015-10",
      "completion_date": "2017-06",
      "has_results": true,
      "last_update_posted_date": "2020-12-29",
      "last_synced_at": "2026-11-17T06:35:50.917Z",
      "location_count": 1,
      "location_summary": "Boston, Massachusetts",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02514824"
    }
  ]
}